PPOLYMARKET

FDA approves Daiichi Sankyo & AstraZeneca's Enhertu?

Yes100%+20.9%

Vol$2.03K

Outcomes2

100%

TradeTrade on Polymarket

MarketPOLYMARKETclosed

FDA approves Daiichi Sankyo & AstraZeneca's Enhertu?

MarketPOLYMARKETclosedTech

FDA approves Daiichi Sankyo & AstraZeneca's Enhertu?

YesYes Price

100¢

|

VolTotal Volume

$2.03K

|

Outcomes

2

Ends

May 18, 2026

about 2 months ago

Trade on Polymarket

FDA approves Daiichi Sankyo & AstraZeneca's Enhertu?

FDA approves Daiichi Sankyo & AstraZeneca's Enhertu?

Yes

100¢

|

Vol

$2.03K

|

Outcomes

2

Yes100.0¢

No0.0¢

Price History

FDA approves Daiichi Sankyo & AstraZeneca's Enhertu?

No historical data available

Price history will appear here when available

Resolution Info

Market Stats

Resolution Countdown

Past Due

May 18, 2026 • 12:00 AM

Last Updated

less than a minute ago

Resolution Information

Status

Closed

Expected Resolution

May 18, 2026

12:00 AM GMT+0

UMA Protocol

Markets are resolved using the UMA optimistic oracle system with community verification.

Accuracy

99.7%

Resolved

15,420

Avg Time

< 2 hours

Disputes

0.3%

Resolution Criteria

As of market creation, the FDA's expected decision date for the specified application is May 18, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Daiichi Sankyo & AstraZeneca's Enhertu as a treatment for neoadjuvant treatment of adult patients with HER2-positive breast cancer by June 1, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.